EUCRU
Eucrates Biomedical Acquisition Corp. [EUCRU] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EUCRU Stock Summary
In the News
EUCRU Financial details
Company Rating
-
Market Cap
47.26M
Income
5.44M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Dec 2022
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
189.93
Current Ratio
2.03
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.55
EPS next Y
-
EPS next Q
-
EPS this Y
45.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
100.22%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
45%
ROE
7%
ROC
-0.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.76-10.63
52W High
-
52W Low
-
RSI
-
Rel Volume
37.03
Avg Volume
581
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.074239
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 581
- Market Capitalization 47.26M
- CEO Mr. Parag Phoolchand Saxena MBA, MS
- Headquarters New York,NY,US
- IPO Date 2020-10-06
Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.
